COMPARATIVE OF INTRAARTICULAR INJECTION BETWEEN DEXTROSE PROLOTHERAPY VERSUS TRIAMCINOLONE ACETONIDE IN KNEE OSTEOARTHRITIS

Widodo Mardi Santoso†, Andhy Indriyono†, Badrul Munir†, Alidha Nur Rakhmani‡, Machlulis Husna†

†Neurology Department, Medical Faculty, Brawijaya University, Saiful Anwar General Hospital, Malang, Indonesia.
‡Public Health Department, Medical Faculty, Brawijaya University, Malang, Indonesia.

Correspondence: widodotta.fk@ub.ac.id

Abstract

Knee osteoarthritis (OA) is one of the most common cartilage degenerative disorders that is a major problem because it causes chronic pain and disability. Therefore the method of treatment and prevention of old age is a big challenge. The results of Dextrose Prolotherapy compared to Triamcinolone therapy research are still varied. Objective: to compare the effectiveness of Dextrose Prolotherapy and Triamcinolone Acetonide (TA) in the treatment of moderate knee OA. True experimental single blind study, at the Neurology Polyclinic Dr. Saiful Anwar General Hospital Malang for 6 months (July–December 2019). Group I: Dextrose Prolotherapy (15%) intraarticularly injected 3 times every 4 weeks and group II: TA one-time intraarticular injection. The parameters studied were The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Score, Numeric Rating Scale (NRS), and Range of Motion (ROM), weeks 0, 4, 8, 12 and 24. Forty samples consisted of: the 20 samples of the Dextrose Prolotherapy group consisted of: male: female = 2 (10%): 18 (90%), age 62.4 + 7.28, BMI 25.6 + 3.69 kg/m², pain duration 22.35 + 10.10 months, history of physiotherapy 40.27 + 20.79 times. Kellgren – Lawrence osteoarthritis severity grade II; 17 (85%), grade III 3 (15%), TA group; male: female = 5 (25%): 15 (75%), age 62.5 + 9.02, BMI 28.4 + 5.01 kg/m², pain duration 15.95 + 16.55 months, history of physiotherapy 34 + 24.87 times. Kellgren – Lawrence osteoarthritis severity grade II; 18 (90%), grade III; 2 (10%). Comparison of NRS at rest Dextrose Prolotherapy vs TA of week 4 (2.60 vs 1.25), week 8 (1.65 vs 1.40), week 12 (0.8 vs 2.05), week 24 (0.75 vs 3.35). Comparison of NRS during activity Dextrose Prolotherapy vs TA week 4 (4.45 vs 3.35), week 8 (3.25 vs 3.55), week 12 (2.55 vs 4.30), week 24 (2.55 vs 5.80). Comparison of ROM flexion Dextrose Prolotherapy vs TA week 4 (127.05° vs 123.60°), week 8 (130.85° vs 122.95°), week 12 (130.85° vs 122.95°), week 24 (131.05° vs 122.10°), Comparison of WOMAC score Dextrose Prolotherapy vs TA week 4 (30.05 vs 22.45), week 8 (22.90 vs 23.95), week 12 (19.30 vs 29.05), week 24 (18.95 vs 35.40). Intraarticular Injection Dextrose Prolotherapy is more effective for the long term based on pain scale NRS, WOMAC score and ROM. Whereas short-term TA is more effective than Dextrose Prolotherapy.

Keyword: Osteoarthritis, Dextrose Prolotherapy, Triamcinolone Acetonide

INTRODUCTION

Osteoarthritis (OA) is a disease that is needed at an age caused by degenerative processes and recovery in articular subcondral tissue and cartilage resulting in biomechanical changes which ultimately cause pain, stiffness, and replacement of articular function. Knee osteoarthritis is a major problem in the world because it is the second leading cause of joint pain and disability in the elderly in western countries after cardiovascular disease (1,2,3).

Treatment methods for knee OA include non pharmacological, pharmacological and surgical procedures. One therapeutic option that is developing and becoming the choice in the treatment of knee OA is intraarticular injection. Intraarticular injection of Triamcinolone Acetonide has been recommended as a treatment for knee OA (4,5,6). However, it only provides short term benefits and there are some adverse side effects (7,8,9).

Prolotherapy is known as proliferative therapy or regeneration injection therapy as a treatment for musculoskeletal pain. Prolotherapy with dextrose has been used for the treatment of knee OA for decades and has recently had efficacy from the results that have been studied. From various previous studies, both injection of Triamcinolone Acetonide and prolotherapy with dextrose in knee osteoarthritis still provide mixed results due to differences in therapeutic methods, evaluation time intervals and therapeutic measurement tools. Because knee OA treatment requires a long time, an alternative non-surgical treatment that is safe, simple,

Article History (Filled by Editor):
Received: August 1, 2020; Accepted: August 20, 2020; Published: September 1, 2020

Cite As: Vancouver style
Santoso WM, Indriyono A, Munir B, Rakhmani AN, Husna M. Comparative of intraarticular injection between dextrose prolotherapy versus triamcinolone acetonide in knee osteoarthritis. Journal of Pain, Vertigo and Headache; 2020;1:22-26
inexpensive, effective, and minimal side effects to reduce pain and improve patient function, then one alternative to knee OA treatment is intraarticular injection of Dextrose Prolotherapy.

Because of the varied research results, the emergence of side effects in the use of Triamcinolone Acetonide and the lack of research data on Triamcinolone Acetonide injection therapy and dextrose prolotherapy, in this study the authors examined how to compare the effectiveness of intraarticular injection of Dextrose Prolotherapy with Triamcinolone Acetonide in the treatment of moderate knee OA at Neurology Clinic Dr. Saiful Anwar Hospital Malang.

The hope if it is proven that Dextrose Prolotherapy has a better effect than Triamcinolone Acetonide, it can be included as one of the standard therapies for the knee OA.

**METHOD**

**Study Design**

This research is a true experimental single blind study to determine differences in the effectiveness of intraarticular injection between Dextrose Prolotherapy and Triamcinolone Acetonide in moderate knee OA patients at Neurology Clinic Dr. Saiful Anwar Hospital Malang.

**Time and Place**

The place for this study at the Neurology Clinic of Dr. Saiful Anwar Hospital. Malang within 6 months (July- December 2019).

**Study Population and Sample**

The study population was all patients with knee OA at Neurology Clinic Dr. Saiful Anwar Hospital Malang. The research sample was the study population that met the inclusion and exclusion criteria, the sample was obtained based on purposive sampling as many as 40, divided into 2 groups namely Dextrose Prolotherapy and Triamcinolone Acetonide, each with 20 people.

**Study Procedure**

In this study, data were entered that included the patient’s identity, history taking and physical examination, recorded the NRS form, WOMAC, and ROM measurements on the diseased knee. In the patient, a knee joint is photographed with standard AP / Lateral skyline view genu which will be read by a radiologist. Each patient on prolotherapy received three intraarticular injections at 1-month intervals at 0, 4 and 8 week injections. In this Dextrose Prolotherapy 15% injection using a composition of 4cc 40% dextrose + 5cc WFI and 1cc 2% lidocaine in a 10cc syringe and injected using a 5cc syringe needle. The composition of intraarticular injection with steroids using Triamcinolone Acetonide 40 mg and 1 ml of 1% lidocaine in a 5cc syringe. In the injection of Triamcinolone Acetonide it is only done once. All examinations are carried out by trained personnel, the results recorded and documented for further analysis.

**RESULT**

The Samples totaled 40; 20 people from the Dextrose Prolotherapy group and 20 people from the Triamcinolone Acetonide group. In the Dextrose Prolotherapy group 15%; females 18 (90%) and males 2 (10%), ages 62.4 ± 7.28, BMI 25.6 ± 3.69 kg/m2, pain duration 22.35 ± 20.10 months, history of physiotherapy 40.27 ± 20.79 times. Kellgren – Lawrence osteoarthritis severity grade II; 17 (85%), grade III; 3 (15%).

In the Triamcinolone Acetonide group; 15 women (75%) and 5 men (25%), age 62.5 ± 9.02, BMI 28.4 ± 5.01 kg/m2, pain duration 15.95 ± 16.55 months, physiotherapy history 34 ± 24.87 times. Kellgren – Lawrence osteoarthritis severity grade II; 18 (90%), grade III; 2 (10%). Patients will be educated to monitor side effects / complications. Side effects of intraarticular injection procedures both with Triamcinolone Acetonide and Dextrose include allergies, pain at the injection site, hematoma, infection, erythema and changes in skin pigmentation and if there are signs of septic arthritis immediately stopped.

During the treatment, the patient is treated the same, which is undergoing physiotherapy twice a week for 3 months in Medical Rehabilitation and is recommended not to take NSAIDs 3 days before injection and for 10 days post injection because it inhibits the recovery process.

Based on demographic findings, Western Ontario and McMaster Universities arthritis index (WOMAC) scores, knee ROM, NRS at rest and activity were recorded. Patients were evaluated shortly before injection (week 0), weeks 4, 8, 12 and 24.

**Table 1. Comparison Profile of Dextrose Prolotherapy 15% and Triamcinolone Acetonide 40 mg**

| Characteristics                        | Dextrose Prolotherapy 15% | Triamcinolone Acetonide 40 mg |
|----------------------------------------|---------------------------|-------------------------------|
| Knees                                  | Right 10 (50%) / Left 10 (50%) | Right 14 (70%) / Left 6 (30%) |
| Age (Y)                                | 62.4 ± 7.28               | 62.5 ± 9.02                   |
| Gender                                 | Male 2 (10%) / Female 18 (90%) | Male 5 (25%) / Female 15 (75%) |
| History                                | Physiotherapy 40.27 ± 20.79 times | Triamcinolone 40 mg 1 ml of 1% lidocaine in a 5cc syringe |
| Duration of Pain (Month)               | 22.35 ± 20.10             | 15.95 ± 16.55                 |
| History of Physiotherapy               | Western Ontario and McMaster Universities arthritis index (WOMAC) scores, knee ROM, NRS at rest and activity were recorded. Patients were evaluated shortly before injection (week 0), weeks 4, 8, 12 and 24. | Based on demographic findings, Western Ontario and McMaster Universities arthritis index (WOMAC) scores, knee ROM, NRS at rest and activity were recorded. Patients were evaluated shortly before injection (week 0), weeks 4, 8, 12 and 24. |
injection (week 0), weeks 4, 8, 12 and 24. The following results are in the form of a comparison chart between Dextrose Prolotherapy and Triamcinolone Acetonide.

**Comparison of NRS at Rest**

![Figure 1. Comparison of NRS at Rest Charts between Dextrose Prolotherapy Injection and Triamcinolone Acetonide.](image)

**Comparison of NRS During Activity**

![Figure 2. Comparison of NRS Activity Charts between Dextrose Prolotherapy Injection and Triamcinolone Acetonide.](image)

**Comparison of ROM Flexion ROM Extension**

![Figure 3. Comparison of ROM Flexion Charts between Dextrose Prolotherapy Injection and Triamcinolone Acetonide.](image)

**Comparison of WOMAC Total Score**

![Figure 4. Comparison of ROM Extension Charts between Dextrose Prolotherapy Injection and Triamcinolone Acetonide.](image)

![Figure 5. Comparison of WOMAC Total Score Chart between Dextrose Prolotherapy Injection and Triamcinolone Acetonide.](image)

**DISCUSSION**

In this study we found evidence of a longer effect to support the use of intraarticular injection of Dextrose Prolotherapy over Triamcinolone Acetonide for the treatment of knee OA in terms of pain relief and function. After 24 weeks of treatment, both injection groups can reduce the severity of symptoms, can increase joint ROM and improve WOMAC score, but Dextrose Prolotherapy seems to be more effective. Our findings are consistent with the results of several previous studies.

Further studies show that the injection of Triamcinolone Acetonide reduces pain sensation and improves function compared to several other treatments for a short time (8).

In another study which confirmed the efficacy of long-term dextrose Prolotherapy which can have an effect of improving pain, stiffness and physical function for 52 weeks on knee OA (10).

Reeves and Hassanein found that Dextrose Prolotherapy 10% removed significant pain, decreased knee swelling and increased range of knee joint motion. They also found based on radiographic features that prolotherapy with dextrose was associated with improvement in the severity of OA (11).

In the short term, Triamcinolone Acetonide reduces symptoms quickly, but after a while the manifestations partly recur. In the Dextrose Prolotherapy group reduces symptoms more slowly and continuously, and the effects of treatment tend to persist. The difference is remarkable in 24 weeks.
when symptoms are reduced and function is improved more in Dextrose Prolotherapy. Our results show that Triamcinolone Acetonide was initially successful, apparently not as effective as Dextrose Prolotherapy for a longer period of time.

In this study we found that Triamcinolone Acetonide was more effective than Dextrose Prolotherapy at week 4 in terms of reducing NRS pain scores. This is consistent with previous studies that the most significant effect on steroid injection is 1 week after injection and its continued effect can be felt at 3–4 weeks after injection. In accordance with the mechanism that Triamcinolone Acetonide is also included in the short-acting corticosteroid group (12,13,14).

Week 8 between Dextrose Prolotherapy and Triamcinolone Acetonide, the effectiveness of the two is no different. In the 12th week until the end of the study in the 24th week it turns out that Dextrose Prolotherapy is more effective than Triamcinolone Acetonide for reducing pain scores. This is because the effects of Triamcinolone Acetonide have begun to diminish while the effects of prolotherapy are slow and constant until the end of the study. In terms of total WOMAC scores, both on Dextrose Prolotherapy and Triamcinolone Triamcinolone the effectiveness is not much different until week 8, but starting from week 12 to week 24 the follow-up on Dextrose Prolotherapy is more effective than Triamcinolone Acetonide. In other words, the effect of treatment reaches its peak after 8–12 weeks, similar to the results of previous studies (15).

The results of this study indicate that intraarticular injection of Dextrose Prolotherapy can be useful as a treatment modality for joint pain OA of the knee. From the point of view of long-term effectiveness, intraarticular injection of Dextrose Prolotherapy can be an adequate pain reliever than an injection of Triamcinolone Acetonide.

Further investigation is needed to evaluate the long-term safety of repeated intraarticular injection with dextrose, adequacy of volume and number of injections, although none of the patients here reported serious side effects.

CONCLUSION

In the long term, Dextrose Prolotherapy is more effective than Triamcinolone Acetonide in patients with moderate knee OA, whereas Triamcinolone Acetonide is more effective in the short term.

ACKNOWLEDGMENT

The researchers would like to thank to Brawijaya University and Dr. Saiful Anwar General Hospital, Malang, East Java, Indonesia for facilitating this research.

REFERENCES

1. Hochberg MC et al. American College of Rheumatology. Recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res; 2012. 64: 465–474. DOI: 10.1002/acr.21596

2. Felson DT. The sources of pain in knee osteoarthritis. Curr Opin Rheumatol; 2005. 17:624–628. DOI: 10.1097/01.bor.0000172800.49120.97

3. Hochberg MC, Perlmutter DL, Hudson JI & Altman RD Preferences in the management of osteoarthritis of the hip and knee: Results of a survey of community-based rheumatologists in the United States. Arthritis Rheum; 1996. 9:170–176. DOI: 10.1002/1529-0131(199606)9:3<170::aid-anr1790090304>3.0.co;2-k

4. Michael JWP, Schlüter-Brust KU & Eysel P. The epidemiology, etiology, diagnosis, and treatment of osteoarthritis of the knee. Dtsch. Aerzteblatt Online; 2010. 107. DOI: 10.3238/arztebl.2010.0152

5. Toopchizadeh V, Babaei-Ghazani A & Eftekhar Sadat, B. Efficiency of Action Potential Simulation (APS) therapy in compare to Transcutaneous Electrical Nerve Stimulation (TENS) in knee osteoarthritis. Life Sci J; 2012. 9:3790–3794. Available from: https://www.researchgate.net/publication/288617645_Efficiency_of_Action_Potential_SimulationAPS_therapy_in_compare_to_Transcutaneous_Electrical_Nerve_Stimulation_TENS_in_knee_osteoarthritis

6. Barron MC & Rubin BR. Managing osteoarthritic knee pain. J Am Osteopath. Assoc; 2007. 107, ES21-27. Available from: https://jaoa.org/article.aspx?articleid=2093546

7. Cusi M. et al. The use of prolotherapy in the sacroiliac joint. Br J Sports Med; 2010. 44:100–104. DOI: 10.1136/bjsm.2007.042044

8. R Joshi. Intra-articular corticosteroid injection for first carpometacarpal osteoarthritis. J Rheumatol; 2005. 32:1305–6. Available from: https://pubmed.ncbi.nlm.nih.gov/15996069/

9. Toker S, Kilincoglu V, Aksakalli E, Gulcan E & Ozkan K. Short-term results of treatment of tennis elbow with anti-inflammatory drugs alone or in combination with local injection of a corticosteroid and anesthetic mixture. Acta Orthop Traumatol Turc; 2008. 42:184–187. DOI: 10.3944/AOTT.2008.184

10. Rabago D et al. Hypertonic dekstrosa injections (prolotherapy) for knee osteoarthritis: Results of a single-arm uncontrolled study with 1-year follow-up. J Altern Complement Med; 2012. 18:408–414. DOI: 10.1089/acm.2011.0030

11. Hashemi M, et al. The effects of prolotherapy with hypertonic dekstrosa versus prolozone (intraartikular ozone) in patients with knee osteoarthritis; 2015. 5:5–8. DOI: 10.5812/aapm.27585

12. R Joshi. Intra-articular corticosteroid injection for first carpometacarpal osteoarthritis. J Rheumatol; 2005. 32:1305–6. Available from: https://pubmed.ncbi.nlm.nih.gov/15996069/
13. Mj, I. et al. Effect of intraarticular steroid injection in addition to physical modalities in osteoarthritis knee; 2014. 23(1):48-54.

14. Godwin M. & Dawes M. Intra-articular steroid injections for painful knees. 241–248. Available from: https://pubmed.ncbi.nlm.nih.gov/15000335/

15. Eslamian F & Amouzandeh B. Therapeutic effects of prolotherapy with intra-articular dekstrosa injection in patients with moderate knee osteoarthritis: a single-arm study with months follow up; 2015. 35–44 DOI:10.1177/1759720X14566